Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Beats on EPS, Stock Up 10.13%

Ligand Pharmaceuticals reported a positive surprise in EPS, which contributed to a strong stock reaction, with shares rising by over 10%. The lack of revenue data leaves some uncertainty, but the significant EPS beat suggests the company is managing costs effectively or benefiting from operational efficiencies. Investors may view this as a sign of potential growth, although clarity on revenue would be beneficial for a complete picture.